PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.15
D/E ratio near Drug Manufacturers - Specialty & Generic median of 0.15. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
-7.89
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.59. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-7.55
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
3.33
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.19. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
68.45%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.63%. Michael Burry would check for aggressive accounting and hidden risks.